Modality
ADC
MOA
PD-L1i
Target
PD-L1
Pathway
Angiogenesis
Ovarian CaPNH
Development Pipeline
Preclinical
~Mar 2011
→ ~Jun 2012
Phase 1
~Sep 2012
→ ~Dec 2013
Phase 2
~Mar 2014
→ ~Jun 2015
Phase 3
~Sep 2015
→ ~Dec 2016
NDA/BLA
~Mar 2017
→ ~Jun 2018
Approved
Sep 2018
→ Jan 2029
ApprovedCurrent
NCT08906706
1,961 pts·PNH
2024-05→TBD·Active
NCT06618230
1,737 pts·Ovarian Ca
2025-12→2025-03·Terminated
NCT04900850
2,872 pts·PNH
2018-09→2029-01·Recruiting
+1 more trial
8,159 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2025-03-221.0y agoPh3 Readout· Ovarian Ca
2027-11-091.6y awayPh3 Readout· PNH
2029-01-092.8y awayPh3 Readout· PNH
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
Approved
Recruit…
Approved
Termina…
Approved
Active
Approved
Termina…
Catalysts
Ph3 Readout
2025-03-22 · 1.0y ago
Ovarian Ca
Ph3 Readout
2027-11-09 · 1.6y away
PNH
Ph3 Readout
2029-01-09 · 2.8y away
PNH
RecruitingActiveTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08906706 | Approved | PNH | Active | 1961 | MRD |
| NCT06618230 | Approved | Ovarian Ca | Terminated | 1737 | EASI-75 |
| NCT04900850 | Approved | PNH | Recruiting | 2872 | Biomarker |
| NCT04523854 | Approved | PNH | Terminated | 1589 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 |